secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viridian Therapeutics, Inc.\DE (VRDN)
CIK:        0001590750
Form:       8-K
Filed at:   2023-10-30T23:59:59+00:00
Accession:  0001193125-23-265717
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 3.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viridian Therapeutics announces new CEO, $185M private placement, next-gen FcRn inhibitors
--------------------------------------------------------------------------------

- Stephen Mahoney appointed President and CEO, succeeds Scott Myers. Base salary $650k, 55% bonus target, option for 1.26M shares.
- $185M private placement: 8.79M shares at $12.38, plus 92,312 convertible preferred shares. Closing expected Nov 1, 2023.
- Discloses preclinical FcRn inhibitors VRDN-006 and VRDN-008; first IND filing by year-end 2024. Targets autoimmune diseases.
- TED pipeline: subcutaneous program selection by end 2023; VRDN-001 THRIVE Phase 3 active TED readout mid-2024.
- Thomas Beetham appointed COO; base salary $500k, 45% bonus target, option for 474k shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590750/000119312523265717/0001193125-23-265717-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590750/000119312523265717/d567471d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-265717

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer